239 related articles for article (PubMed ID: 8319607)
1. Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans.
Groopman JD; Wild CP; Hasler J; Junshi C; Wogan GN; Kensler TW
Environ Health Perspect; 1993 Mar; 99():107-13. PubMed ID: 8319607
[TBL] [Abstract][Full Text] [Related]
2. Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa.
Groopman JD; Hall AJ; Whittle H; Hudson GJ; Wogan GN; Montesano R; Wild CP
Cancer Epidemiol Biomarkers Prev; 1992; 1(3):221-7. PubMed ID: 1339082
[TBL] [Abstract][Full Text] [Related]
3. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China.
Groopman JD; Zhu JQ; Donahue PR; Pikul A; Zhang LS; Chen JS; Wogan GN
Cancer Res; 1992 Jan; 52(1):45-52. PubMed ID: 1727385
[TBL] [Abstract][Full Text] [Related]
4. Quantification and validation of enzyme immunoassay for urinary aflatoxin B1-N7-guanine adduct for biological monitoring of aflatoxins.
Nayak S; Sashidhar RB; Bhat RV
Analyst; 2001 Feb; 126(2):179-83. PubMed ID: 11235100
[TBL] [Abstract][Full Text] [Related]
5. Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats.
Groopman JD; DeMatos P; Egner PA; Love-Hunt A; Kensler TW
Carcinogenesis; 1992 Jan; 13(1):101-6. PubMed ID: 1733561
[TBL] [Abstract][Full Text] [Related]
6. Molecular dosimetry in rat urine of aflatoxin-N7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography.
Groopman JD; Hasler JA; Trudel LJ; Pikul A; Donahue PR; Wogan GN
Cancer Res; 1992 Jan; 52(2):267-74. PubMed ID: 1728400
[TBL] [Abstract][Full Text] [Related]
7. Identification of aflatoxin M1-N7-guanine in liver and urine of tree shrews and rats following administration of aflatoxin B1.
Egner PA; Yu X; Johnson JK; Nathasingh CK; Groopman JD; Kensler TW; Roebuck BD
Chem Res Toxicol; 2003 Sep; 16(9):1174-80. PubMed ID: 12971806
[TBL] [Abstract][Full Text] [Related]
8. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.
Egner PA; Wang JB; Zhu YR; Zhang BC; Wu Y; Zhang QN; Qian GS; Kuang SY; Gange SJ; Jacobson LP; Helzlsouer KJ; Bailey GS; Groopman JD; Kensler TW
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14601-6. PubMed ID: 11724948
[TBL] [Abstract][Full Text] [Related]
9. Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males.
Mykkänen H; Zhu H; Salminen E; Juvonen RO; Ling W; Ma J; Polychronaki N; Kemiläinen H; Mykkänen O; Salminen S; El-Nezami H
Int J Cancer; 2005 Jul; 115(6):879-84. PubMed ID: 15723309
[TBL] [Abstract][Full Text] [Related]
10. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts.
Yu MW; Lien JP; Liaw YF; Chen CJ
Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):613-9. PubMed ID: 8824363
[TBL] [Abstract][Full Text] [Related]
11. DNA damage by mycotoxins.
Wang JS; Groopman JD
Mutat Res; 1999 Mar; 424(1-2):167-81. PubMed ID: 10064859
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of aflatoxin B1-N7-guanine adduct in urine by enzyme-linked immunosorbent assay coupled with immunoaffinity chromatography.
Vidyasagar T; Vyjayanthi V; Sujatha N; Rao BS; Bhat RV
J AOAC Int; 1997; 80(5):1013-22. PubMed ID: 9325579
[TBL] [Abstract][Full Text] [Related]
13. Molecular dosimetry of aflatoxin DNA adducts in humans and experimental rat models.
Groopman JD; Roebuck BD; Kensler TW
Prog Clin Biol Res; 1992; 374():139-55. PubMed ID: 1320272
[TBL] [Abstract][Full Text] [Related]
14. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya.
Autrup H; Seremet T; Wakhisi J; Wasunna A
Cancer Res; 1987 Jul; 47(13):3430-3. PubMed ID: 3034416
[TBL] [Abstract][Full Text] [Related]
15. Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats.
Bennett RA; Essigmann JM; Wogan GN
Cancer Res; 1981 Feb; 41(2):650-4. PubMed ID: 6778611
[TBL] [Abstract][Full Text] [Related]
16. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.
Qian GS; Ross RK; Yu MC; Yuan JM; Gao YT; Henderson BE; Wogan GN; Groopman JD
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):3-10. PubMed ID: 8118382
[TBL] [Abstract][Full Text] [Related]
17. The use of monoclonal antibody affinity columns for assessing DNA damage and repair following exposure to aflatoxin B1.
Groopman JD; Kensler TW
Pharmacol Ther; 1987; 34(2):321-34. PubMed ID: 3120202
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence quantification of aflatoxin N7-guanine adducts.
Weaver VM; Groopman JD
Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):669-74. PubMed ID: 7881340
[TBL] [Abstract][Full Text] [Related]
19. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review.
Wogan GN; Kensler TW; Groopman JD
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2012; 29(2):249-57. PubMed ID: 21623489
[TBL] [Abstract][Full Text] [Related]
20. Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry.
Egner PA; Groopman JD; Wang JS; Kensler TW; Friesen MD
Chem Res Toxicol; 2006 Sep; 19(9):1191-5. PubMed ID: 16978023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
